Moreover, the ratio of CD8+ to CD4+ T cells was ninefold higher in the brains than in the dLNs of T-αFGL2-treated survivors, suggesting that CD8+ T cells, but not CD4+ T cells, were the primary memory T cells controlling glioma cell growth, and that these CD8+ T cells were only resident in the brain. This evidence concerns the gene CD4 and central nervous system cancer.